Article
Oncology
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Eva Martinez de Castro, Ana Custodio, Carles Pericay Pijaume, Raquel Hernandez, Gema Aguado, Natalia Castro Unanua, Juana Maria Cano, Flora Lopez, Marcelo Garrido, Ana Fernandez Montes, Laura Visa, Manuel Sanchez Canovas, Maria Luisa Limon, Nieves Martinez Lago, Paola Pimentel, Alicia Hurtado, Aitor Azkarate, Federico Longo, Marc Diez, Aranzazu Arias-Martinez, Tamara Sauri, Alfonso Martin Carnicero, Monserrat Mangas, Marta Martin Richard, Monica Granja, Avinash Ramchandani, Carolina Hernandez Perez, Paula Cerda, Aitziber Gil-Negrete, Mariona Calvo, Rosario Vidal Tocino, Javier Gallego
Summary: The study developed an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer. Results showed that DPF was associated with increased progression-free survival and overall survival compared to PF, but with higher rates of serious adverse events, particularly hematological effects.
Article
Oncology
Shubham Sharma, J. Connor Wells, Wilma M. Hopman, Joseph C. Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E. Hay, Christopher M. Booth
Summary: Canada has a long history of leading practice-changing clinical trials in oncology, but they are overly reliant on industry support. The proportion of trials identifying new treatments with substantial clinical benefit is very low, indicating a need for renewed investment in cancer clinical trials in Canada.
Article
Medicine, General & Internal
Massimo Torreggiani, Antoine Chatrenet, Antioco Fois, Maria Rita Moio, Beatrice Maze, Jean Philippe Coindre, Romain Crochette, Mickael Sigogne, Samuel Wacrenier, Lena Lecointre, Conrad Breuer, Hafedh Fessi, Giorgina Barbara Piccoli
Summary: The study investigated the referral pattern of CKD patients in a large nephrology unit, finding that CKD staging increases with age and comparing the impact of different formulas on estimating kidney function. The results showed that regardless of the equation used, the current referral pattern does not affect the need for CKD care in elderly patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Letter
Multidisciplinary Sciences
Eduardo F. Motti
Summary: This is a letter to the editor.
Article
Medicine, General & Internal
Zainab Aziz, Sophie Wagner, Alice Agyekum, Yoanna S. Pumpalova, Matthew Prest, Francesca Lim, Sheila Rustgi, Fay Kastrinos, William M. Grady, Chin Hur
Summary: Despite recommendations for universal screening, adherence to colorectal cancer screening in the US is low. This study evaluated the cost-effectiveness of liquid biopsy for colorectal cancer screening and found that colonoscopy was the most cost-effective strategy, while liquid biopsy was not cost-effective at its current cost and screening performance.
Article
Medicine, General & Internal
Connie M. Ulrich, Kathleen Knafl, Anessa M. Foxwell, Qiuping Zhou, Cynthia Paidipati, Deborah Tiller, Sarah J. Ratcliffe, Gwenyth R. Wallen, Therese S. Richmond, Mary Naylor, Thomas F. Gordon, Christine Grady, Victoria Miller
Summary: Patient-participants who withdrew from cancer clinical trials described intense symptoms and emotions, as well as a sense of limited options and short life span awareness. Communication focusing on posttrial needs is crucial throughout the trial to help patients navigate posttrial steps effectively. Research should target responsible and ethical transitions post clinical trial, including timing and types of discussions and who should initiate these discussions with patients and their families.
Review
Urology & Nephrology
Ben Sprangers, Mark A. Perazella, Stuart M. Lichtman, Mitchell H. Rosner, Kenar D. Jhaveri
Summary: Chemotherapeutic agents used to treat cancer often have narrow therapeutic indices and potentially serious toxicities. Limited data on the safe and effective dosing of these drugs in patients with chronic kidney disease (CKD) contribute to the exclusion of CKD patients from cancer drug trials, preventing optimal clinical care for this population.
KIDNEY INTERNATIONAL REPORTS
(2022)
Review
Oncology
Ming Jin, Lulu Xie, Ni Mao, Jianzi Wei, Junchao Chen, Xuefen Chen, Huijuan Mao
Summary: This study identified 222 eligible trials from 19 countries, encompassing 17 specific cancer types and 32 symptoms. The most common cancer types included breast cancer, head and neck cancer, colorectal cancer, lung cancer, and gastric cancer, accounting for almost half of all registered trials (48.2%). The top five symptoms included chemotherapy-induced peripheral neuropathy (CIPN), cancer-related pain, cancer-related fatigue, chemotherapy-induced nausea and vomiting (CINV), and gastrointestinal dysfunction.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Obstetrics & Gynecology
Adithya Shastry, Barbara Bajuk, Mohamed E. Abdel-Latif
Summary: Infants who were eligible but not enrolled in the study were born earlier and had higher risks, including lower Apgar scores and more complications. Therefore, obtaining consent in advance may lead to bias in study results. Retrospective consent or waiver of consent may improve the generalizability of clinical trials involving neonatal and emergency cases.
JOURNAL OF PERINATOLOGY
(2022)
Article
Oncology
Lorenzo Livi, Giuseppe Barletta, Francesca Martella, Calogero Saieva, Isacco Desideri, Carlotta Bacci, Maria Riccarda Del Bene, Mario Airoldi, Domenico Amoroso, Luigi Coltelli, Vieri Scotti, Carlotta Becherini, Luca Visani, Viola Salvestrini, Matteo Mariotti, Fulvia Pedani, Marco Bernini, Luis Sanchez, Lorenzo Orzalesi, Jacopo Nori, Simonetta Bianchi, Iacopo Olivotto, Icro Meattini
Summary: The study aimed to evaluate whether pharmacological cardioprevention could reduce subclinical heart damage in breast cancer patients undergoing anthracycline-based chemotherapy. The results of the interim analysis suggested that cardioprotective pharmacological strategies were well tolerated and appeared to protect against cancer therapy-related left ventricular ejection fraction decline and heart remodeling.
Article
Clinical Neurology
Raphael Golebiowski, Meghna P. Mansukhani, Bhanu Prakash Kolla
Summary: Recent Phase III trials of hypnotic medications have severely restrictive eligibility criteria, with only 3 out of 100 referred insomnia patients receiving these medications being eligible. Only 12% would have been eligible if the criterion of prior or concurrent trial of cognitive behavioral therapy for insomnia were set aside. Medical comorbidities, daytime napping, and sleep apnea were the main reasons for exclusion. These findings question the generalizability of regulatory studies and call for future trials with less-restrictive criteria.
JOURNAL OF CLINICAL SLEEP MEDICINE
(2023)
Article
Oncology
Aakash Desai, Justin F. Gainor, Aparna Hegde, Alison M. Schram, Guiseppe Curigiliano, Sumanta Pal, Stephen V. Liu, Balazs Halmos, Roman Groisberg, Enrique Grande, Tomislav Dragovich, Marc Matrana, Neeraj Agarwal, Sant Chawla, Shumei Kato, Gilberto Morgan, Pashtoon M. Kasi, Benjamin Solomon, Herbert H. Loong, Haeseong Park, Toni K. Choueiri, Ishwaria M. Subbiah, Naveen Pemmaraju, Vivek Subbiah
Summary: The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease, and it is necessary to prioritize cancer patients, including those participating in oncology clinical trials, for vaccination. Data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited, but the benefits of vaccination are likely to far outweigh the risks of adverse events.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Neurosciences
Mayssa Hachem, Mirja Kaizer Ahmmed, Houda Nacir-Delord
Summary: Phospholipidomics is a specialized branch of lipidomics that provides valuable insights into the metabolism and activities of phospholipids in brain disorders. By identifying specific phospholipid biomarkers, it has the potential to enhance diagnosis and treatment options for neurological diseases.
MOLECULAR NEUROBIOLOGY
(2023)
Article
Oncology
Carmen Criscitiello, Antonio Marra, Stefania Morganti, Paola Zagami, Sara Gandini, Angela Esposito, Giuseppe Curigliano
Summary: This study retrospectively analyzed the clinical characteristics and outcomes of patients with metastatic breast cancer treated with targeted therapy, immunotherapy, and combination therapy from 2014 to 2019 at a medical institution. The results showed that patients with triple negative breast cancer had poorer outcomes, and targeted therapy was associated with improved response rates and progression-free survival. Patients with fewer metastatic sites and baseline lactate dehydrogenase below the upper limit of normal had better overall survival.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Joseph M. Unger, Anna B. Moseley, Christabel K. Cheung, Raymond U. Osarogiagbon, Banu Symington, Scott D. Ramsey, Dawn L. Hershman
Summary: Patients with cancer from socioeconomically disadvantaged areas participating in clinical trials have worse survival outcomes, with higher area-level socioeconomic deprivation associated with poorer overall, progression-free, and cancer-specific survival. The etiology of this disparity may be related to reduced access to supportive care or post-protocol therapy and/or differences in health status not reflected by protocol selection criteria.
JOURNAL OF CLINICAL ONCOLOGY
(2021)